No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
www.mochida.co.jpNo one on the platform currently holds 4534.T.
No tracked institution reports a position in 4534.T as of their last filing.
No one on the platform has traded 4534.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.9% | 7.6% | 9.4% | — | — | — |
| Rev. Growth % | 11.2% | 2.6% | ||||
| Profit Margin % | 6.8% | 6.5% | 7.0% | |||
| Free Cash Flow Margin % | -8.6% | -0.4% | 2.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $110.0B | +1.9% | $208.30 | $208.30–$208.30 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 4534.TMochida Pharmaceutical Co., Ltd. | $3250.00 | +0.78% | $114.9B | — |
| 2175.TSMS Co., Ltd. | $2666.00 | -0.26% | $218.8B | — |
| 4521.TKaken Pharmaceutical Co., Ltd. | $3905.00 | +0.51% | $147.9B | — |
| 4553.TTowa Pharmaceutical Co., Ltd. | $3625.00 | +2.11% | $178.5B | — |
| 4559.TZeria Pharmaceutical Co., Ltd. | $2014.00 | -0.10% | $88.8B | — |
| 4569.TKYORIN Holdings, Inc. | $1124.00 | +0.09% | $64.6B | — |
| 4886.TASKA Pharmaceutical Holdings Co.,Ltd. | $2110.00 | +1.34% | $59.9B | — |
Source: Financial Modeling Prep · peers by sector/industry